Reference list - Prostate – Screening, benign enlargement and cancer
1. Auvinen A, Tammela T, Stenman U-H, Uusi-Erkkila I, Leinonen J, Schroder FH et al. Screening for prostate cancer using serum prostate-specific antigen: A randomised, population-based pilot study in Finland. British Journal of Cancer Vol 74.(4.) (pp.568.-572.), 1996.

2. Bangma CH, Blijenberg BG, Schroder FH. Prostate-specific antigen: Its clinical use and application in screening for prostate cancer. Scandinavian Journal of Clinical & Laboratory Investigation - Supplement Vol 55.(221.) (pp.35.-44.), 1995.

3. Bangma CH, Rietbergen JW, Kranse R, Blijenberg BG, Petterson K, Schroder FH et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. Journal d.Urologie Vol 157.(6.) (pp.2191.-2198.), 1997.

4. Beemsterboer PM, Kranse R, De KH, Habbema JF, Schroder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). International Journal of Cancer Vol 84.(4.) (pp.437.-441.), 1999.

5. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998;52:455-61.

6. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27:25-31.

 



The Andropause Society - Registered Charity No. 1088008

The Information on this site is provided for information only, and is not meant to substitute for the advice of your own physician or other medical professional. Copyright © 2000 - 2009 The Andropause Society.